Response to "Lorlatinib Exposed: A Far from Optimal Dose"

Clin Pharmacol Ther. 2022 Jun;111(6):1197-1198. doi: 10.1002/cpt.2580. Epub 2022 Mar 31.

Authors

Joseph Chen¹, Ana Ruiz-Garcia¹, Leonard P James¹, Gerson Peltz¹, Holger Thurm¹, Jill Clancy¹, Jennifer Hibma¹

Affiliation

¹ Pfizer Inc., New York, New York, USA.

PMID: 35358326
DOI: 10.1002/cpt.2580

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aminopyridines* / adverse effects
Humans
Lactams
Lactams, Macrocyclic
Pyrazoles*

Substances

Aminopyridines
Lactams
Lactams, Macrocyclic
Pyrazoles
lorlatinib